Possession of Codeine Cough Syrup Without License Attracts NDPS Act Rigors: Patna High Court - 2025-08-27

Cough Syrup Possession Under NDPS: Patna High Court Denies Bail Citing 'Commercial Quantity' Limits

In a significant ruling clarifying the application of the Narcotic Drugs and Psychotropic Substances (NDPS) Act to pharmaceutical preparations, the Patna High Court has denied bail to an individual found in possession of 40 bottles of cough syrup containing codeine phosphate. The judgment, delivered by Justice Jitendra Kumar, reinforces the state’s stringent approach toward unauthorized possession of medicinal narcotics.

The Case Background

Petitioner Nilendra Kumar Karan was arrested in March 2025 after Sashastra Seema Bal (SSB) personnel intercepted a four-wheeler near the India-Nepal border. During the search, officers recovered 40 bottles of cough syrup—each containing codeine phosphate and triprolidine hydrochloride. The petitioner was subsequently charged under sections 21 and 22 of the NDPS Act.

After his plea for anticipatory bail was rejected by the Principal Sessions Judge-cum-Special Court in Madhubani, the matter reached the High Court. The central legal question involved whether cough syrup containing codeine requires authorization under the NDPS Act even in therapeutic formulations, and if the total weight of the seized syrup constitutes a "commercial quantity" under current statutory guidelines.

Arguments on Both Sides

Counsel for the petitioner argued that the cough syrup is an essential drug and not a narcotic substance, suggesting the case should fall under the Drugs and Cosmetics Act, 1940, rather than the more severe NDPS Act. Relying on * Vibhor Rana v. Union of India *, the defense contended that since the codeine concentration was below 2.5%, the substance was exempted from "manufactured drug" status.

The State, however, countered that the NDPS Act is a special law intended to regulate essential narcotic drugs and that unlicensed possession of such preparations—regardless of concentration—violates the code of authorized distribution. They argued that the Hira Singh v. Union of India precedent mandates that the weight of neutral carrier substances be included when determining if the contraband reaches "commercial quantity," thereby triggering the strict bail conditions under Section 37 of the NDPS Act.

Legal Analysis: The NDPS-Drugs and Cosmetics Intersection

The Court observed that the NDPS Act and the Drugs and Cosmetics Act operate in tandem rather than exclusion. Justice Kumar noted that while codeine-based syrups are medically accepted, their unauthorized transport or possession for distribution falls squarely within the regulatory ambit of the NDPS Act. The judgment clarified that recent judicial precedents, such as those from the Delhi and Jammu & Kashmir High Courts, correctly prioritize the notification and control mechanisms established under Chapter VA of the NDPS Rules over broader therapeutic exemptions when the accused lacks valid licensure.

Key Observations

The judgment clarifies that the "liberal" application of the Drugs and Cosmetics Act cannot override the specific prohibitions of the NDPS Act in the absence of valid permits. Key remarks from the Court include:

• "The NDPS Act and the Rules made thereunder are in addition to and not in derogation of the Drugs and Cosmetics Act, 1940."
• "In case of seizure of mixture of narcotic drugs or psychotropic substances with one or more neutral substance(s), the quantity of neutral substance(s) is not to be excluded and it has to be taken into consideration... while determining the commercial quantity."
• "Negation of bail is the rule and its grant is an exception under sub-clause (ii) of clause (b) of Section 37 (1)."
• "Violation of Section 42 of the NDPS Act being a question of fact can be decided during the trial only and is not available to the petitioner in a Bail proceeding."

The Verdict and Its Impact

Finding that the quantity seized exceeded commercial thresholds and lacking evidence of authorized possession, Justice Kumar rejected the bail petition. The ruling serves as a stern reminder to pharmaceutical aggregators and individual possessors alike: without rigorous compliance with licensing and permit requirements, the possession of even small-concentration therapeutic narcotics will invite the full force of the NDPS Act, making bail a difficult legal hurdle to clear.